InvestSMART

Healius Limited (ASX:HLS)

ALERT: Price-sensitive ASX Announcement for HLS
Current share price for HLS : $0.385 -0.43 (-52.76%)+
Announcement
Release
18 Feb 2026 8:16AM
Price at Release
$0.815
Full Release
download
Summary
Healius Limited's Half Year 2026 Results Presentation highlighted a group revenue growth of 3.8% to $688.1 million, underpinned by an increase in Pathology revenue. The company's underlying EBITDA experienced a significant rise, driven by cost optimization and strategic investments in technology, such as AI and the Medway Collectors and Results Portals. Agilex Biolabs contributed to the margin expansion through its strategic focus on large molecule development. Healius's efforts in labour optimization and digital transformation led to substantial cost savings, enhancing their operational efficiency.
Key Points
  • Healius Limited reported a group revenue growth of $25.5 million, an increase of 3.8%, to $688.1 million for the first half of 2026.
  • Pathology revenue rose by $22.5 million, or 3.5%, reaching $666.3 million.
  • The group's underlying EBITDA increased by $14.2 million, marking a 13.1% rise to $122.2 million.
  • Pathology's EBITDA went up by $12.3 million (11.7%) to $117.4 million, while Agilex Biolabs' EBITDA increased by $1.9 million (65.5%) to $4.8 million.
  • A significant technology investment was made, including the launch of AI co-workers and the Medway Collectors and Results Portals.
  • The company achieved a net cash position of $11.6 million by the end of December 2025.
  • Healius is focused on cost reduction strategies, resulting in annualized support cost savings and a digital transformation program.
  • Labour optimization and cost management have been key drivers for the operational efficiency gains reported.
  • The strategic pivot towards large molecule work by Agilex Biolabs has contributed positively to margin expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.